Oric Pharmaceuticals Inc
ORIC8.430USD
+0.160+1.93%
Close 12/24, 13:00（ET）Quotes delayed by 15 min
820.05MMarket Cap
LossP/E TTM
More Details of Oric Pharmaceuticals Inc Company
ORIC Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on improving patients’ lives by Overcoming Resistance In Cancer. The Company is advancing a diverse pipeline of clinical and discovery stage therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology and key tumor dependencies. The Company's clinical-stage product candidates include ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and ORIC-114, a brain penetrant inhibitor that selectively targets EGFR exon 20, HER2 exon 20 and EGFR atypical mutations, being developed across multiple genetically defined cancers. In addition, the Company is also developing multiple discovery stage precision medicines targeting other hallmark cancer resistance mechanisms. Its out-licensing candidates include ORIC-533 and ORIC-613.
Oric Pharmaceuticals Inc Info
Ticker SymbolORIC
Company nameOric Pharmaceuticals Inc
IPO dateApr 24, 2020
CEOChacko (Jacob M)
Number of employees115
Security typeOrdinary Share
Fiscal year-endApr 24
Address240 E. Grand Ave
CitySOUTH SAN FRANCISCO
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94080
Phone16503885600
Websitehttps://oricpharma.com/
Ticker SymbolORIC
IPO dateApr 24, 2020
CEOChacko (Jacob M)
Company Executives of Oric Pharmaceuticals Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Jacob M. Chacko, M.D.
Dr. Jacob M. Chacko, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
528.65K
-14.61%
Dr. Richard A. (Rich) Heyman, Ph.D.
Dr. Richard A. (Rich) Heyman, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
261.57K
+14.34%
Dr. Kevin Brodbeck, Ph.D.
Dr. Kevin Brodbeck, Ph.D.
Chief Technical Officer
Chief Technical Officer
--
--
Mr. Dominic G. Piscitelli, CPA
Mr. Dominic G. Piscitelli, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Pratik S. Multani, M.D.
Dr. Pratik S. Multani, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Mardi C. Dier
Ms. Mardi C. Dier
Independent Director
Independent Director
--
--
Mr. Steven L. (Steve) Hoerter
Mr. Steven L. (Steve) Hoerter
Independent Director
Independent Director
--
--
Dr. Lori A. Kunkel, M.D.
Dr. Lori A. Kunkel, M.D.
Independent Director
Independent Director
--
--
Dr. Angie J. You, Ph.D.
Dr. Angie J. You, Ph.D.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Jacob M. Chacko, M.D.
Dr. Jacob M. Chacko, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
528.65K
-14.61%
Dr. Richard A. (Rich) Heyman, Ph.D.
Dr. Richard A. (Rich) Heyman, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
261.57K
+14.34%
Dr. Kevin Brodbeck, Ph.D.
Dr. Kevin Brodbeck, Ph.D.
Chief Technical Officer
Chief Technical Officer
--
--
Mr. Dominic G. Piscitelli, CPA
Mr. Dominic G. Piscitelli, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Pratik S. Multani, M.D.
Dr. Pratik S. Multani, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Mardi C. Dier
Ms. Mardi C. Dier
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Nextech Invest, Ltd.
7.35%
EcoR1 Capital, LLC
6.91%
VR Adviser, LLC
6.77%
Viking Global Investors LP
6.75%
Pfizer Inc
5.52%
Other
66.69%
Shareholders
Shareholders
Proportion
Nextech Invest, Ltd.
7.35%
EcoR1 Capital, LLC
6.91%
VR Adviser, LLC
6.77%
Viking Global Investors LP
6.75%
Pfizer Inc
5.52%
Other
66.69%
Shareholder Types
Shareholders
Proportion
Investment Advisor/Hedge Fund
32.03%
Investment Advisor
30.06%
Venture Capital
22.48%
Hedge Fund
13.47%
Corporation
5.52%
Private Equity
3.74%
Research Firm
2.07%
Sovereign Wealth Fund
1.97%
Individual Investor
1.31%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
298
97.41M
100.29%
+9.46M
2025Q2
288
93.19M
110.15%
+12.20M
2025Q1
294
83.96M
99.59%
+456.78K
2024Q4
284
80.39M
113.18%
-3.73M
2024Q3
272
78.70M
112.04%
-2.29M
2024Q2
265
76.25M
113.03%
-1.57M
2024Q1
276
71.21M
105.62%
-1.02M
2023Q4
259
57.91M
108.09%
+1.21M
2023Q3
260
55.20M
103.62%
-1.09M
2023Q2
255
52.76M
117.11%
+8.95M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Nextech Invest, Ltd.
7.16M
7.37%
+1.88M
+35.51%
Jun 30, 2025
EcoR1 Capital, LLC
6.73M
6.93%
+5.11M
+315.81%
Jul 29, 2025
VR Adviser, LLC
6.60M
6.79%
--
--
Jun 30, 2025
Viking Global Investors LP
6.57M
6.77%
--
--
Jun 30, 2025
Pfizer Inc
5.38M
5.54%
--
--
Jun 30, 2025
The Vanguard Group, Inc.
3.12M
3.22%
-81.50K
-2.54%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
3.43M
3.53%
-969.78K
-22.06%
Jun 30, 2025
SR One Capital Management, LP
4.62M
4.75%
+100.45K
+2.22%
Aug 12, 2025
New Enterprise Associates (NEA)
4.12M
4.24%
+1.92M
+87.59%
Jun 30, 2025
Alkeon Capital Management LLC
3.75M
3.86%
+409.32K
+12.25%
Jun 30, 2025
View more
Related ETFs
Updated: Tue, Dec 2
Updated: Tue, Dec 2
Name
Proportion
iShares Genomics Immunology and Healthcare ETF
1.12%
Virtus LifeSci Biotech Clinical Trials ETF
0.92%
Tema Oncology ETF
0.39%
State Street SPDR S&P Biotech ETF
0.28%
Optimize Strategy Index ETF
0.27%
iShares Health Innovation Active ETF
0.2%
Direxion Daily S&P Biotech Bull 3X Shares
0.17%
iShares Micro-Cap ETF
0.15%
ProShares Ultra Nasdaq Biotechnology
0.13%
Invesco Nasdaq Biotechnology ETF
0.12%
View more
iShares Genomics Immunology and Healthcare ETF
Proportion1.12%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion0.92%
Tema Oncology ETF
Proportion0.39%
State Street SPDR S&P Biotech ETF
Proportion0.28%
Optimize Strategy Index ETF
Proportion0.27%
iShares Health Innovation Active ETF
Proportion0.2%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.17%
iShares Micro-Cap ETF
Proportion0.15%
ProShares Ultra Nasdaq Biotechnology
Proportion0.13%
Invesco Nasdaq Biotechnology ETF
Proportion0.12%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Oric Pharmaceuticals Inc?
The top five shareholders of Oric Pharmaceuticals Inc are:
Nextech Invest, Ltd. holds 7.16M shares, accounting for 7.37% of the total shares.
EcoR1 Capital, LLC holds 6.73M shares, accounting for 6.93% of the total shares.
VR Adviser, LLC holds 6.60M shares, accounting for 6.79% of the total shares.
Viking Global Investors LP holds 6.57M shares, accounting for 6.77% of the total shares.
Pfizer Inc holds 5.38M shares, accounting for 5.54% of the total shares.
Nextech Invest, Ltd. holds 7.16M shares, accounting for 7.37% of the total shares.
EcoR1 Capital, LLC holds 6.73M shares, accounting for 6.93% of the total shares.
VR Adviser, LLC holds 6.60M shares, accounting for 6.79% of the total shares.
Viking Global Investors LP holds 6.57M shares, accounting for 6.77% of the total shares.
Pfizer Inc holds 5.38M shares, accounting for 5.54% of the total shares.
What are the top three shareholder types of Oric Pharmaceuticals Inc?
The top three shareholder types of Oric Pharmaceuticals Inc are:
Nextech Invest, Ltd.
EcoR1 Capital, LLC
VR Adviser, LLC
Nextech Invest, Ltd.
EcoR1 Capital, LLC
VR Adviser, LLC
How many institutions hold shares of Oric Pharmaceuticals Inc (ORIC)?
As of 2025Q3, 298 institutions hold shares of Oric Pharmaceuticals Inc, with a combined market value of approximately 97.41M, accounting for 100.29% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -9.86%.
What is the biggest source of revenue for Oric Pharmaceuticals Inc?
In --, the -- business generated the highest revenue for Oric Pharmaceuticals Inc, amounting to -- and accounting for --% of total revenue.
